Clinical commissioning policy statement: Selective Internal Radiotherapy (SIRT) in the treatment of secondary liver cancers (all ages)

Document first published:
Page updated:
Publication type:

Selective Internal Radiotherapy (SIRT) is not recommended to be available as a routine commissioning treatment option for the treatment of (1) neuroendocrine tumour liver metastases (NETLM); (2) liver metastases of other less common radiotherapy sensitive tumours, within the criteria set out in this document.